Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

Patients with myelodysplastic syndrome harboring a TP53 mutation experienced a survival benefit with allogeneic hematopoietic cell transplantation compared with non-HCT treatment regardless of TP53 ...

Patients with TP53 germline variants have an increased risk of secondary sarcoma post-radiation therapy. The 15-year risk of sarcoma for TP53 pathogenic variant carriers is 8.8%, higher than the ...

Researchers have discovered that a specific mutation in the cancer cells of an aggressive type of blood cancer can prevent novel immunotherapies such as CAR T-cell therapy from working. Their study ...

Adequate CD19-positive cell content is required to reliably identify both dominant and subclonal TP53 mutations. DNA was isolated in parallel from 2 different sample types from this patient: ...

PRINCETON, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ...

Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL). This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...